Literature DB >> 17626598

In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection.

Katty Terrazas-Aranda1, Yven Van Herrewege, Paul J Lewi, Jens Van Roey, Guido Vanham.   

Abstract

Several classes of microbicides are being evaluated for the prevention of sexual HIV transmission. In vivo, the infectious dose and viral source involved in transmission remain uncertain and it is likely that women will use microbicides both before and after high-risk HIV exposure. Therefore, we evaluated HIV entry inhibitors (EIs) and reverse transcriptase inhibitors (RTIs) for their ability to block cell-free and cell-associated HIV-1 infection in co-cultures of monocyte-derived dendritic cells (MO-DC) and CD4+ T-cells using settings of pre- and post-exposure prophylaxis. In the pre-exposure assay, where compound was present before, during and 24 h after infection, all tested EIs (BMS806, TAK779 and T20) and RTIs (PMPA, TMC120 and UC781) blocked infection with 10(-4) multiplicity of infection (MOI) of cell-free virus at a dose between 100 and 10,000 nM, dependent on the compound used. At 10(-3) MOI, however, only T20 and the RTIs completely blocked infection. Furthermore, in experiments with cell-associated virus, EIs were ineffective, whereas RTIs actively blocked infection with similar potency as in the experiments with cell-free virus. In the post-exposure assay, where compound was added 2 h after infection and remained present for 24 h, EIs were inactive whereas RTIs blocked cell-free and cell-associated viral infections equally efficiently. Moreover, post-exposure prophylaxis initiated 24 h after infection with cell-free or cell-associated HIV-1 was still effective with 1,000 nM of TMC120. Both EIs and RTIs were non-cytotoxic at any tested concentration for MO-DC and CD4+ T-cells in co-culture. Our study shows that RTIs are potent inhibitors of cell-free and cell-associated virus used either in pre- or post-exposure settings. It highlights that parameters such as viral input, viral source, the time of compound addition and the target cells should be considered in microbicides evaluation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17626598     DOI: 10.1177/095632020701800304

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  8 in total

1.  Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

Authors:  José das Neves; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

2.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Design of a semisolid vaginal microbicide gel by relating composition to properties and performance.

Authors:  Alamelu Mahalingam; Eric Smith; Judit Fabian; Festo R Damian; Jennifer J Peters; Meredith R Clark; David R Friend; David F Katz; Patrick F Kiser
Journal:  Pharm Res       Date:  2010-09-15       Impact factor: 4.200

4.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

Authors:  Alamelu Mahalingam; Adam P Simmons; Shweta R Ugaonkar; Karen M Watson; Charlene S Dezzutti; Lisa C Rohan; Robert W Buckheit; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

6.  Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Daria Hazuda; Paul Lewi; Roberta Costi; Roberto Di Santo; Andrea Cara; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

7.  Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

Authors:  P Fletcher; S Harman; H Azijn; N Armanasco; P Manlow; D Perumal; M-P de Bethune; J Nuttall; J Romano; R Shattock
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

8.  Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies.

Authors:  Gurinder Singh; Roopa S Pai
Journal:  ScientificWorldJournal       Date:  2014-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.